PHS Stock Overview
Engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products. More details
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 4/6 |
Past Performance | 2/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Community vs My Fair Value
Select a narrative for quick price alerts from the community, or create your own.
Photocure ASA Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | NOK 4.12 |
52 Week High | NOK 5.26 |
52 Week Low | NOK 4.24 |
Beta | 0.62 |
1 Month Change | 0% |
3 Month Change | n/a |
1 Year Change | n/a |
3 Year Change | n/a |
5 Year Change | -36.71% |
Change since IPO | -30.76% |
Recent News & Updates
Recent updates
Shareholder Returns
PHS | DE Pharmaceuticals | DE Market | |
---|---|---|---|
7D | 0% | -6.6% | 0.8% |
1Y | n/a | -27.7% | 14.6% |
Return vs Industry: Insufficient data to determine how PHS performed against the German Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how PHS performed against the German Market.
Price Volatility
PHS volatility | |
---|---|
PHS Average Weekly Movement | n/a |
Pharmaceuticals Industry Average Movement | 5.7% |
Market Average Movement | 6.5% |
10% most volatile stocks in DE Market | 12.9% |
10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: PHS's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine PHS's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1993 | 100 | Dan Schneider | www.photocure.com |
Photocure ASA, together with its subsidiaries, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products. It operates through Commercial Franchise and Development Portfolio segments. The company offers Hexvix/Cysview for the detection and management of bladder cancer.
Photocure ASA Fundamentals Summary
PHS fundamental statistics | |
---|---|
Market cap | €114.96m |
Earnings (TTM) | €184.39k |
Revenue (TTM) | €45.94m |
623.5x
P/E Ratio2.5x
P/S RatioIs PHS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
PHS income statement (TTM) | |
---|---|
Revenue | NOK 532.69m |
Cost of Revenue | NOK 32.11m |
Gross Profit | NOK 500.57m |
Other Expenses | NOK 498.44m |
Earnings | NOK 2.14m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
Jul 30, 2025
Earnings per share (EPS) | 0.08 |
Gross Margin | 93.97% |
Net Profit Margin | 0.40% |
Debt/Equity Ratio | 0% |
How did PHS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/05/17 21:53 |
End of Day Share Price | 2025/03/10 00:00 |
Earnings | 2025/03/31 |
Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Photocure ASA is covered by 5 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Hans Bohn | Beringer Finance AB |
null null | Brookline Capital Markets |
Geir Holom | DNB Markets |